Myrisoph Capital
Overview
Myrisoph Capital is a private equity firm specializing in turning around undervalued companies across various sectors. The firm focuses on small to medium-sized enterprises (SMEs) that require expert advice and mentorship to elevate their businesses. Their investment approach is hands-on, aiming to revitalize and scale operations effectively. The firm's strategy encompasses a broad range of industries, including medical, laboratory, biotech, fintech, healthcare, regenerative medicine, predictive medicine, stem cell banking, financial services, technology, consumer services, real estate, infrastructure, manufacturing, and retail. They invest at various stages, from seed to late-stage, including buyouts, turnarounds, and distressed assets. Geographically, Myrisoph Capital has a presence in the United States, United Arab Emirates, Switzerland, Poland, and Germany. Myrisoph Capital has a successful track record in turning around undervalued companies in the medical, laboratory, and biotech sectors. They have been involved in strategic agreements, such as the one with Esperite N.V. in 2019, where they became the exclusive global licensee of the CryoSave brand for a minimum period of ten years. This partnership aimed to revitalize the CryoSave brand and position it among the top five family stem cell banks worldwide. Additionally, in 2025, Myrisoph Capital, through its subsidiary CSG-BIO, reached a strategic agreement with PBKM sp. z o.o. (FamiCord Group) to clarify legal disputes and ensure the continued care of cord blood and tissue samples previously under the care of the bankrupt Swiss Company Cryo-Save AG. Myrisoph Capital's investment philosophy centers on providing hands-on management and operational efficiency to create value. They focus on localized deals, leveraging local market knowledge and contacts to generate attractive returns. Their expertise in turning around undervalued companies and their commitment to operational excellence have been key factors in their investment success.
Investment Focus
- Undervalued companies requiring turnaround
- SMEs seeking expert advice and mentorship
- Companies in need of capital injection
- Businesses aiming for operational efficiency and hands-on management
Portfolio Companies
Reach Myrisoph Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Myrisoph Capital
What sectors does Myrisoph Capital invest in?
Myrisoph Capital invests in Financial Services, Technology, Healthcare, Real Estate, Infrastructure and Retail, and is based in California, United States. Myrisoph Capital is listed as a private equity in the ConnectSafely investor database.
What stage does Myrisoph Capital invest at?
Myrisoph Capital backs companies at Seed, Early Stage, Growth, Late Stage, Buyout and Turnaround, writing cheques of 1M - 50M.
Which regions does Myrisoph Capital invest in?
Myrisoph Capital invests across United States, Germany, United Arab Emirates, Switzerland and Poland.
Who are the partners at Myrisoph Capital?
Team members listed for Myrisoph Capital include Hassan Alhassani (Chief Executive Officer).
What companies has Myrisoph Capital invested in?
Myrisoph Capital's portfolio includes NOW Money, Cryo-Save Arabia FZ-LLC, CSG-BIO SA, CellSave Arabia FZ-LLC, PBKM sp. z o.o. and FamiCord AG.
How do I contact Myrisoph Capital?
Myrisoph Capital's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
